Drug designer: New tool reveals mutations that cause HIV-drug resistance

July 8, 2011 in HIV & AIDS

Protease inhibitor drugs are one of the major weapons in the fight against HIV, the virus that causes AIDS, but their effectiveness is limited as the virus mutates and develops resistance to the drugs over time. Now a new tool has been developed to help predict the location of the mutations that lead to drug resistance.

First discovered in 1995, protease inhibitor drugs have dramatically reduced the number of AIDS deaths. Taken in combination with two other anti-HIV drugs, protease inhibitors work by halting the action of the protease enzyme, a protein produced by HIV that is necessary for replication of the virus. However, almost half of who initially respond to treatment with protease inhibitors develop strains and stop responding to treatment within eight to 10 months.

Currently there are nine FDA approved protease inhibitors, and 21 most common drug-resistant mutations.

The main reason for the short-term effectiveness of the drug has to do with the evolution of the drug within the body, said the study's author, Yi Mao, a postdoctoral fellow at the National Institute for Mathematical and .

In the new study, published today in the journal BMC Structural Biology, Mao used a mathematical modeling technique called elastic network modeling to examine the physical properties and interactions of the proteins. The model reveals where mutations are occurring during the evolution of the proteins and how these mutations help the virus survive.

"With this kind of knowledge, better strategies for designing anti-HIV drugs could be developed," Mao said.

HIV kills the body's , called CD4 cells. Once the number of CD4 cells dips below 200, an HIV patient enters the last stage of his or her disease: Acquired Immune Deficiency Syndrome, or AIDS. The first cases of AIDS were reported thirty years ago. Since then, more than 60 million people have been infected with HIV, and more than 30 million people have died from AIDS. Today an estimated 34 million people worldwide are living with HIV – 1.2 million in the U.S.

More information: Mao Y. 2011. Dynamical Basis for Drug Resistance of HIV-1 Protease. BMC Structural Biology. Published online 8 July 2011. 11:31. doi:10.1186/1472-6807-11-31

Provided by National Institute for Mathematical and Biological Synthesis

not rated yet  

Rank not rated yet
Relevant PhysicsForums posts

More news stories

Mortality rates decrease, chronic disease rates increase among HIV+ ICU patients

The expanded use of antiretrovirals, potent drugs used to treat retroviral infections such as human immunodeficiency virus (HIV), has been linked to significant decreases in hospital mortality rates among severely ill HIV-positive(HIV+) ...

HIV & AIDS created May 23, 2012 | popularity not rated yet | comments 0

Newly discovered breast milk antibodies help neutralize HIV

Antibodies that help to stop the HIV virus have been found in breast milk. Researchers at Duke University Medical Center isolated the antibodies from immune cells called B cells in the breast milk of infected mothers in Malawi, ...

HIV & AIDS created May 22, 2012 | popularity 5 / 5 (3) | comments 1 | with audio podcast

Reactions to HIV drug have autoimmune cause, reports AIDS journal

Potentially severe hypersensitivity reactions to the anti-HIV drug abacavir occur through an autoimmune mechanism, resulting from the creation of drug-induced immunogens that are attacked by the body's immune system, according ...

HIV & AIDS created May 22, 2012 | popularity 5 / 5 (1) | comments 0

Is the U.S. ready for home HIV tests?

At the pharmacy, you can buy anything from tea kettles to Tylenol. But what if you could buy a rapid HIV test over the counter and test yourself in the privacy of your own home?

HIV & AIDS created May 21, 2012 | popularity not rated yet | comments 0 | with audio podcast

Reduced glycerin formulation of tenofovir vaginal gel safe for rectal use

A change in the formulation of tenofovir gel, an anti-HIV gel developed for vaginal use, may make it safer to use in the rectum, suggests a study published online this week in the Journal of Antimicrobial Chemotherapy. In lab ...

HIV & AIDS created May 17, 2012 | popularity 5 / 5 (1) | comments 0


New study should end debate over magnesium treatment for preventing poor outcome after haemorrhagic stroke

An international randomised trial and meta-analysis published Online First in The Lancet should put an end to the debate about the use of intravenous magnesium sulphate to prevent poor outcomes after haemorrhagic stroke. The in ...

Progestin treatment for polycystic ovarian syndrome may reduce pregnancy chances

(Medical Xpress) -- The hormone progestin, often given as a first step in infertility treatment for polycystic ovary syndrome (PCOS), appears to decrease the odds of conception and of giving birth, according to a study by ...

World 'no tobacco day' puts spotlight on dangers of smoking

It’s not just smokers who are at-risk when it comes to tobacco smoke exposure—and the health concerns of smoking cigarettes are not limited to the most known consequence: lung cancer. 

Nonsmoking lung cancer survivor encourages others to consider risk

Carol Seibert had an upper respiratory infection she just couldn’t seem to shake. The timing of her illness was awful, as she had just returned from a trip to Florida for her youngest son’s surgery and was preparing ...

Like curry? New biological role identified for compound used in ancient medicine

Scientists have just identified a new reason why some curry dishes, made with spices humans have used for thousands of years, might be good for you.

Amino acid consumption associated with how fast cancer cells divide

For almost a century, researchers have known that cancer cells have peculiar appetites, devouring glucose in ways that normal cells do not. But glucose uptake may tell only part of cancer's metabolic story. Researchers from ...